These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22861668)

  • 1. Thirty years of preclinical safety evaluation of biopharmaceuticals: Did scientific progress lead to appropriate regulatory guidance?
    Kooijman M; van Meer PJ; Moors EH; Schellekens H
    Expert Opin Drug Saf; 2012 Sep; 11(5):797-801. PubMed ID: 22861668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Overregulation and unnecessary animal testing: requirements for market approval of biopharmaceuticals too rigid].
    Schellekens H
    Ned Tijdschr Geneeskd; 2012; 156(50):A5723. PubMed ID: 23231875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.
    Vargas HM; Amouzadeh HR; Engwall MJ
    Expert Opin Drug Saf; 2013 Jan; 12(1):91-102. PubMed ID: 23170873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.
    Morford LL; Bowman CJ; Blanset DL; Bøgh IB; Chellman GJ; Halpern WG; Weinbauer GF; Coogan TP
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):359-80. PubMed ID: 21770023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview status of preclinical safety assessment for immunomodulatory biopharmaceuticals.
    Green JD; Black LE
    Hum Exp Toxicol; 2000 Apr; 19(4):208-12. PubMed ID: 10918509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The application of ICH S6 to the preclinical safety evaluation of plasma derivative therapeutic products.
    Lewis RM; Cavagnaro J
    Biologicals; 2010 Jul; 38(4):494-500. PubMed ID: 20359910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory guidelines for biosimilars in Malaysia.
    Abas A
    Biologicals; 2011 Sep; 39(5):339-42. PubMed ID: 21784655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacovigilance of biopharmaceuticals: challenges remain.
    Giezen TJ; Mantel-Teeuwisse AK; Leufkens HG
    Drug Saf; 2009; 32(10):811-7. PubMed ID: 19722725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current regulatory and scientific considerations for approving biosimilars in Iran.
    Hadavand N; Valadkhani M; Zarbakhsh A
    Biologicals; 2011 Sep; 39(5):325-7. PubMed ID: 21873077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Conference on Harmonisation; addendum to International Conference on Harmonisation Guidance on S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2012 May; 77(97):29665-6. PubMed ID: 22616137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
    Lebrec H; Narayanan P; Nims R
    J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals.
    Martin PL; Breslin W; Rocca M; Wright D; Cavagnaro J
    Birth Defects Res B Dev Reprod Toxicol; 2009 Jun; 86(3):176-203. PubMed ID: 19462404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop.
    Buckley LA; Benson K; Davis-Bruno K; Dempster M; Finch GL; Harlow P; Haggerty HG; Hart T; Kinter L; Leighton JK; McNulty J; Roskos L; Saber H; Stauber A; Tabrizi M
    Int J Toxicol; 2008; 27(4):303-12. PubMed ID: 18821393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
    Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
    Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manufacturing, regulatory and commercial challenges of biopharmaceuticals production: a Finnish perspective.
    Närhi M; Nordström K
    Eur J Pharm Biopharm; 2005 Apr; 59(3):397-405. PubMed ID: 15760720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolites in safety testing.
    Robison TW; Jacobs A
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical assessments of european union marketing authorisation applications for immunomodulatory biopharmaceuticals.
    Liminga U
    Hum Exp Toxicol; 2000 Apr; 19(4):257-60. PubMed ID: 10918519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory aspects of oncology drug safety evaluation: past practice, current issues, and the challenge of new drugs.
    Rosenfeldt H; Kropp T; Benson K; Ricci MS; McGuinn WD; Verbois SL
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):125-33. PubMed ID: 20045015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.